To assess whether interrogation of EP of ODIs at different disease stages might help identifying genes relevant to the human disease, we interrogated the transcriptomes of PDA from the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) for differential expression of selected genes (C7, MUC1, NT5E, TGFB1, FN1, and ITGA5) in clinically relevant subgroups. The gene discussed is NT5E; the disease is Patent ductus arteriosus.